Anti-TNF-alpha-induced psoriasis: case report of an unusual adverse event.
Aslanidis
Spyros
S
Pyrpasopoulou
Athina
A
Leontsini
Maria
M
Zamboulis
Chryssanthos
C
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D011565:Psoriasis / Q000276:immunology* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab